Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Dermatologic 7Other hematologic neoplasm 4Sarcoma 2Myeloid 2Thoracic 1Plasma cell 1Gastrointestinal 1Classical hematology 1

Conditions

Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Methoxsalen × Thoracic × Clear all
NCT06646016 2025-12-26

EPIC

Therakos LLC

Phase 2 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡